Lisa Hensley (microbiologist)

Last updated

Hensley in 2008 Dr. Lisa Hensley accepts an award at The Outstanding Young Persons of the World ceremony in New Delhi (cropped).jpg
Hensley in 2008

Lisa Ellen [1] Hensley is the associate director of science at the Office of the Chief Scientist, National Institute of Allergy and Infectious Disease Integrated Research Facility in Frederick, Maryland. She was previously a civilian microbiologist in the virology division of the United States Army Medical Research Institute of Infectious Diseases (USAMRIID). Hensley is one of the premier researchers of some of the world's most dangerous infections, including Ebola hemorrhagic fever, Lassa fever, the coronavirus diseases Severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), [2] and smallpox. She has been involved in research uncovering critical mechanisms in the pathogenesis of hemorrhagic fever viruses, and has used those discoveries to develop candidate therapeutic drugs for their treatment.

Hensley is a native of Winston-Salem, North Carolina. Before working with USAMRIID, she worked as a staff fellow at the National Institute of Diabetes and Digestive and Kidney Diseases, part of the National Institutes of Health (NIH). She also held graduate teaching and research posts at the University of North Carolina at Chapel Hill, where she achieved her PhD (advisor Ralph S. Baric), [1] and at Duke University Medical Center in Durham, North Carolina. Hensley joined USAMRIID in 1998 as a research associate in the Pathology Division. She has co-authored over 180 publications in peer-reviewed scientific journals on a variety of infectious disease topics. She now serves as the Chief of Viral Therapeutics, Virology Division at USAMRIID.

A 2006 Lancet article co-authored by Hensley published results on progress for treatment of Marburg virus, a severe hemorrhagic virus with potential utility as a biological weapon. [3] The study tested the efficacy of a new post-exposure vaccine for Marburg using a rhesus macaque model. It found that rhesus monkeys exposed to the vaccine survived a high-dose lethal challenge of Marburg for at least 80 days, while the control monkeys died after day 12. [3] A co-authored 2005 paper in PLOS Medicine reviewed the development of a vaccine for Lassa fever, for which there are currently no vaccines licensed. Their trial vaccine elicited a protective immune response in nonhuman primates, and when infected with Lassa, they showed no evidence of clinical disease.

Hensley is the subject of a chapter in journalist Richard Preston's 2002 book Demon in the Freezer , which covers the history of smallpox eradication and the current debates over remaining smallpox stocks. In Chapter 5, "A Woman With a Peaceful Life", Preston recounts Hensley's beginnings as a researcher with USAMRIID and her eventual recruitment to the CDC to collaborate on smallpox research. Hensley was part of the team responsible for the first nonhuman smallpox infection (in monkeys), proving the potential for continued live-animal smallpox research. Some would argue[ who? ] that the experiment's success bolsters the argument of "retentionists", who oppose elimination of smallpox stores largely so that they can continue to be researched.

In 2007, Hensley was recognized as one of the year's "Ten Outstanding Young Americans" (TOYA) by the United States Junior Chamber (Jaycees). The award honors Americans ages 18–40 who "exemplify the best attributes of the nation’s young people". In 2008, she was selected as one of the year's Ten Outstanding Young Persons of the world ("TOYP") by JCI (Junior Chamber International). Similar to the TOYA award, this program recognizes young people who excel in their chosen fields and exemplify the best attributes of the world's young people.

Works consulted

Related Research Articles

<span class="mw-page-title-main">Lassa fever</span> Viral disease spread by a type of mouse

Lassa fever, also known as Lassa hemorrhagic fever, is a type of viral hemorrhagic fever caused by the Lassa virus. Many of those infected by the virus do not develop symptoms. When symptoms occur they typically include fever, weakness, headaches, vomiting, and muscle pains. Less commonly there may be bleeding from the mouth or gastrointestinal tract. The risk of death once infected is about one percent and frequently occurs within two weeks of the onset of symptoms. Of those who survive, about a quarter have hearing loss, which improves within three months in about half of these cases.

<span class="mw-page-title-main">Marburg virus disease</span> Human viral disease

Marburg virus disease is a viral hemorrhagic fever in human and non-human primates caused by either of the two Marburgviruses: Marburg virus (MARV) and Ravn virus (RAVV). Its clinical symptoms are very similar to those of Ebola virus disease (EVD).

<span class="mw-page-title-main">Biological hazard</span> Biological material that poses serious risks to the health of living organisms

A biological hazard, or biohazard, is a biological substance that poses a threat to the health of living organisms, primarily humans. This could include a sample of a microorganism, virus or toxin that can adversely affect human health. A biohazard could also be a substance harmful to other living beings.

<i>Indiana vesiculovirus</i> Species of virus

Indiana vesiculovirus, formerly Vesicular stomatitis Indiana virus is a virus in the family Rhabdoviridae; the well-known Rabies lyssavirus belongs to the same family. VSIV can infect insects, cattle, horses and pigs. It has particular importance to farmers in certain regions of the world where it infects cattle. This is because its clinical presentation is identical to the very important foot and mouth disease virus.

<span class="mw-page-title-main">Viral hemorrhagic fever</span> Type of illnesses

Viral hemorrhagic fevers (VHFs) are a diverse group of animal and human illnesses. VHFs may be caused by five distinct families of RNA viruses: the families Filoviridae, Flaviviridae, Rhabdoviridae, and several member families of the Bunyavirales order such as Arenaviridae, and Hantaviridae. All types of VHF are characterized by fever and bleeding disorders and all can progress to high fever, shock and death in many cases. Some of the VHF agents cause relatively mild illnesses, such as the Scandinavian nephropathia epidemica, while others, such as Ebola virus, can cause severe, life-threatening disease.

<i>The Hot Zone</i> 1995 nonfiction book by Richard Preston

The Hot Zone: A Terrifying True Story is a best-selling 1994 nonfiction thriller by Richard Preston about the origins and incidents involving viral hemorrhagic fevers, particularly ebolaviruses and marburgviruses. The basis of the book was Preston's 1992 New Yorker article "Crisis in the Hot Zone".

<span class="mw-page-title-main">Crimean–Congo hemorrhagic fever</span> Disease of humans and other animals

Crimean–Congo hemorrhagic fever (CCHF) is a viral disease. Symptoms of CCHF may include fever, muscle pains, headache, vomiting, diarrhea, and bleeding into the skin. Onset of symptoms is less than two weeks following exposure. Complications may include liver failure. Survivors generally recover around two weeks after onset.

<i>The Demon in the Freezer</i> 2002 nonfiction book by Richard Preston

The Demon in the Freezer is a 2002 nonfiction book on the biological weapon agents smallpox and anthrax and how the American government develops defensive measures against them. It was written by journalist Richard Preston, also author of the best-selling book The Hot Zone (1994), about ebolavirus outbreaks in Africa and Reston, Virginia and the U.S. government's response to them.

<span class="mw-page-title-main">United States Army Medical Research Institute of Infectious Diseases</span> U.S. Army counter-biological warfare research institution

The United States Army Medical Research Institute of Infectious Diseases is the U.S Army's main institution and facility for defensive research into countermeasures against biological warfare. It is located on Fort Detrick, Maryland, near Washington, D.C., and is a subordinate lab of the United States Army Medical Research and Development Command (USAMRDC), headquartered on the same installation.

Clarence James Peters, Jr is a physician, field virologist and former U.S. Army colonel. He is noted for his efforts in trying to stem epidemics of exotic infectious diseases such as the Ebola virus, Hanta virus and Rift Valley fever (RVF). He is an eminent authority on the virology, pathogenesis and epidemiology of hemorrhagic fever viruses.

The species Sudan ebolavirus is a virological taxon included in the genus Ebolavirus, family Filoviridae, order Mononegavirales. The species has a single virus member, Sudan virus (SUDV). The members of the species are called Sudan ebolaviruses. It was discovered in 1977 and causes Ebola clinically indistinguishable from the ebola Zaire strain, but is less transmissible than it. Unlike with ebola Zaire there is no vaccine available.

<span class="mw-page-title-main">Marburg virus</span> Species of filamentous virus responsible for hemorrhagic fever

Marburg virus (MARV) is a hemorrhagic fever virus of the Filoviridae family of viruses and a member of the species Marburg marburgvirus, genus Marburgvirus. It causes Marburg virus disease in primates, a form of viral hemorrhagic fever. The virus is considered to be extremely dangerous. The World Health Organization (WHO) rates it as a Risk Group 4 Pathogen. In the United States, the National Institute of Allergy and Infectious Diseases ranks it as a Category A Priority Pathogen and the Centers for Disease Control and Prevention lists it as a Category A Bioterrorism Agent. It is also listed as a biological agent for export control by the Australia Group.

<span class="mw-page-title-main">Ebola</span> Viral hemorrhagic fever of humans and other primates caused by ebolaviruses

Ebola, also known as Ebola virus disease (EVD) and Ebola hemorrhagic fever (EHF), is a viral hemorrhagic fever in humans and other primates, caused by ebolaviruses. Symptoms typically start anywhere between two days and three weeks after infection. The first symptoms are usually fever, sore throat, muscle pain, and headaches. These are usually followed by vomiting, diarrhoea, rash and decreased liver and kidney function, at which point some people begin to bleed both internally and externally. It kills between 25% and 90% of those infected – about 50% on average. Death is often due to shock from fluid loss, and typically occurs between six and 16 days after the first symptoms appear. Early treatment of symptoms increases the survival rate considerably compared to late start. An Ebola vaccine was approved by the US FDA in December 2019.

rVSV-ZEBOV vaccine Vaccine against Ebola virus disease

Recombinant vesicular stomatitis virus–Zaire Ebola virus (rVSV-ZEBOV), also known as Ebola Zaire vaccine live and sold under the brand name Ervebo, is an Ebola vaccine for adults that prevents Ebola caused by the Zaire ebolavirus. When used in ring vaccination, rVSV-ZEBOV has shown a high level of protection. Around half the people given the vaccine have mild to moderate adverse effects that include headache, fatigue, and muscle pain.

<span class="mw-page-title-main">Ebola vaccine</span> Vaccine against Ebola

Ebola vaccines are vaccines either approved or in development to prevent Ebola. As of 2022, there are only vaccines against the Zaire ebolavirus. The first vaccine to be approved in the United States was rVSV-ZEBOV in December 2019. It had been used extensively in the Kivu Ebola epidemic under a compassionate use protocol. During the early 21st century, several vaccine candidates displayed efficacy to protect nonhuman primates against lethal infection.

A notifiable disease is one which the law requires to be reported to government authorities.

Recombinant vesicular stomatitis virus vaccines are vaccines made using recombinant Indiana vesiculovirus, including:

Patricia Ann Webb was a microbiologist known for her work in characterising and classifying severe contagious diseases including Machupo, Lassa and Ebola viruses.

<span class="mw-page-title-main">Viral vector vaccine</span> Type of vaccine

A viral vector vaccine is a vaccine that uses a viral vector to deliver genetic material (DNA) that can be transcribed by the recipient's host cells as mRNA coding for a desired protein, or antigen, to elicit an immune response. As of April 2021, six viral vector vaccines, four COVID-19 vaccines and two Ebola vaccines, have been authorized for use in humans.

References

  1. 1 2 "Molecular mechanisms of the cross-species transmission of mouse hepatitis virus". ProQuest. 9818345. Retrieved 15 June 2021.
  2. ↑ "Hensley, Lisa E." Scopus. Retrieved 15 June 2021.
  3. 1 2 Daddario-DiCaprio, Kathleen M; Geisbert, Thomas W; Ströher, Ute; Geisbert, Joan B; Grolla, Allen; Fritz, Elizabeth A; Fernando, Lisa; Kagan, Elliott; Jahrling, Peter B; Hensley, Lisa E; Jones, Steven M; Feldmann, Heinz (1 April 2006). "Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment". The Lancet. 367 (9520): 1399–1404. doi:10.1016/S0140-6736(06)68546-2.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.